LoT1
N = 17,077,696

LoT2
N = 9,724,029

LoT3
N = 6,317,768

LoT4
N = 4,378,963

Prescribing specialist,^* n (%)

Primary care provider

12,220,654 (71.6%)

6,732,749 (69.2%)

4,364,404 (69.1%)

2,965,790 (67.7%)

Primary care physician

9,302,461 (54.5%)

4,995,425 (51.4%)

3,278,823 (51.9%)

2,236,060 (51.1%)

Nurse practitioner/
physician assistant

2,918,193 (17.1%)

1,737,324 (17.9%)

1,085,581 (17.2%)

729,730
(16.7%)

Cardiologist

1,566,008
(9.2%)

1,130,709 (11.6%)

836,051
(13.2%)

656,771
(15.0%)

Nephrologist

237,303 (1.4%)

189,872 (2.0%)

141,888 (2.2%)

114,659 (2.6%)

Endocrinologist

87,208 (0.5%)

47,264 (0.5%)

30,778 (0.5%)

21,296 (0.5%)

Infectious disease specialist

34,361 (0.2%)

16,997 (0.2%)

10,368 (0.2%)

6,721 (0.2%)

Other

676,222 (4.0%)

476,781 (4.9%)

266,515 (4.2%)

177,957 (4.1%)

Specialist not specified

2,255,940 (13.2%)

1,129,657 (11.6%)

667,764
(10.6%)

435,769
(10.0%)

Combination therapy with 2+ classes, n (%)

8,012,319 (46.9%)

5,254,610 (54.0%)

3,620,098 (57.3%)

2,504,016 (57.2%)

Fixed-dose combination

2,453,370 (14.4%)

1,131,719 (11.6%)

683,444
(10.8%)

413,716
(9.4%)

Free-dose combination

5,558,949 (32.6%)

4,122,891 (42.4%)

2,936,654 (46.5%)

2,090,300 (47.7%)

Number of patients receiving guideline-recommended antihypertensive classes,^† n (%)

Using at least 1 of the classes

13,519,507 (79.2%)

7,299,206 (75.1%)

4,743,062 (75.1%)

3,183,325 (72.7%)

Monotherapy using only the classes

6,158,723 (36.1%)

2,655,685 (27.3%)

1,564,670 (24.8%)

1,023,128 (23.4%)

Combination therapy with 2+ classes using 2 of the 4 classes

3,840,964 (47.9%)

2,169,261 (41.3%)

1,435,466 (39.7%)

927,950 (37.1%)

Combination therapy with 3+ classes using 3 of the 4 classes

647,436 (24.3%)

419,322 (21.4%)

288,133 (20.2%)

188,851 (18.6%)

Combination therapy with 4+ classes using 3 of the 4 classes

257,224 (40.3%)

182,109 (34.7%)

131,182 (33.4%)

92,084 (31.7%)